Pfizer Sells $4.5 Billion of Bonds to Repay Obligations
This article is for subscribers only.
Pfizer Inc., the U.S. drugmaker seeking to acquire AstraZeneca Plc, sold $4.5 billion of bonds to repay securities that mature within a year.
The offering, which was increased from $4.25 billion, included $1.5 billion of 2.1 percent, five-year notes that yielded 48 basis points more than similar-maturity Treasuries, according to data compiled by Bloomberg.